126 related articles for article (PubMed ID: 37898375)
21. GPX2 is a potential therapeutic target to induce cell apoptosis in lenvatinib against hepatocellular carcinoma.
Tan W; Zhang K; Chen X; Yang L; Zhu S; Wei Y; Xie Z; Chen Y; Shang C
J Adv Res; 2023 Feb; 44():173-183. PubMed ID: 36725188
[TBL] [Abstract][Full Text] [Related]
22. Heterogeneity, inherent and acquired drug resistance in patient-derived organoid models of primary liver cancer.
Xian L; Zhao P; Chen X; Wei Z; Ji H; Zhao J; Liu W; Li Z; Liu D; Han X; Qian Y; Dong H; Zhou X; Fan J; Zhu X; Yin J; Tan X; Jiang D; Yu H; Cao G
Cell Oncol (Dordr); 2022 Oct; 45(5):1019-1036. PubMed ID: 36036881
[TBL] [Abstract][Full Text] [Related]
23. Caspase-3-Induced Activation of SREBP2 Drives Drug Resistance via Promotion of Cholesterol Biosynthesis in Hepatocellular Carcinoma.
Mok EHK; Leung CON; Zhou L; Lei MML; Leung HW; Tong M; Wong TL; Lau EYT; Ng IOL; Ding J; Yun JP; Yu J; Zhu HL; Lin CH; Lindholm D; Leung KS; Cybulski JD; Baker DM; Ma S; Lee TKW
Cancer Res; 2022 Sep; 82(17):3102-3115. PubMed ID: 35767704
[TBL] [Abstract][Full Text] [Related]
24. [The regulation of APGAT4 on the growth and lenvatinib resistance of hepatocellular carcinoma].
Li Z; Yang NH; Li B; Sun CY
Zhonghua Gan Zang Bing Za Zhi; 2023 Apr; 31(4):408-414. PubMed ID: 37248980
[No Abstract] [Full Text] [Related]
25. ST6GAL1 Is a Novel Serum Biomarker for Lenvatinib-Susceptible FGF19-Driven Hepatocellular Carcinoma.
Myojin Y; Kodama T; Maesaka K; Motooka D; Sato Y; Tanaka S; Abe Y; Ohkawa K; Mita E; Hayashi Y; Hikita H; Sakamori R; Tatsumi T; Taguchi A; Eguchi H; Takehara T
Clin Cancer Res; 2021 Feb; 27(4):1150-1161. PubMed ID: 33288659
[TBL] [Abstract][Full Text] [Related]
26. ID1 promotes hepatocellular carcinoma proliferation and confers chemoresistance to oxaliplatin by activating pentose phosphate pathway.
Yin X; Tang B; Li JH; Wang Y; Zhang L; Xie XY; Zhang BH; Qiu SJ; Wu WZ; Ren ZG
J Exp Clin Cancer Res; 2017 Nov; 36(1):166. PubMed ID: 29169374
[TBL] [Abstract][Full Text] [Related]
27. The role of proline rich tyrosine kinase 2 (Pyk2) on cisplatin resistance in hepatocellular carcinoma.
Geng W; Ng KT; Sun CK; Yau WL; Liu XB; Cheng Q; Poon RT; Lo CM; Man K; Fan ST
PLoS One; 2011; 6(11):e27362. PubMed ID: 22096562
[TBL] [Abstract][Full Text] [Related]
28. Revealing the suppressive role of protein kinase C delta and p38 mitogen-activated protein kinase (MAPK)/NF-κB axis associates with lenvatinib-inhibited progression in hepatocellular carcinoma in vitro and in vivo.
Wu CH; Hsu FT; Chao TL; Lee YH; Kuo YC
Biomed Pharmacother; 2022 Jan; 145():112437. PubMed ID: 34864311
[TBL] [Abstract][Full Text] [Related]
29. Nek2 augments sorafenib resistance by regulating the ubiquitination and localization of β-catenin in hepatocellular carcinoma.
Deng L; Sun J; Chen X; Liu L; Wu D
J Exp Clin Cancer Res; 2019 Jul; 38(1):316. PubMed ID: 31319849
[TBL] [Abstract][Full Text] [Related]
30. SREBP2 inhibitor betulin sensitizes hepatocellular carcinoma to lenvatinib by inhibiting the mTOR/IL-1β pathway.
Fan M; Chen Z; Shao W; Chen Y; Lin Z; Yi C; Li Y; Lu L; Zhou Y; Lin J
Acta Biochim Biophys Sin (Shanghai); 2023 Jul; 55(9):1479-1486. PubMed ID: 37434430
[TBL] [Abstract][Full Text] [Related]
31. WDR4/TRIM28 is a novel molecular target linked to lenvatinib resistance that helps retain the stem characteristics in hepatocellular carcinomas.
Han WY; Wang J; Zhao J; Zheng YM; Chai XQ; Gao C; Cai JB; Ke AW; Fan J; Gao PT; Sun HX
Cancer Lett; 2023 Aug; 568():216259. PubMed ID: 37279851
[TBL] [Abstract][Full Text] [Related]
32. Hepatocellular carcinoma cells loss lenvatinib efficacy in vitro through autophagy and hypoxia response-derived neuropilin-1 degradation.
Fernández-Palanca P; Payo-Serafín T; San-Miguel B; Méndez-Blanco C; Tuñón MJ; González-Gallego J; Mauriz JL
Acta Pharmacol Sin; 2023 May; 44(5):1066-1082. PubMed ID: 36376373
[TBL] [Abstract][Full Text] [Related]
33. Targeting ACYP1-mediated glycolysis reverses lenvatinib resistance and restricts hepatocellular carcinoma progression.
Wang S; Zhou L; Ji N; Sun C; Sun L; Sun J; Du Y; Zhang N; Li Y; Liu W; Lu W
Drug Resist Updat; 2023 Jul; 69():100976. PubMed ID: 37210811
[TBL] [Abstract][Full Text] [Related]
34. RARRES1 inhibits hepatocellular carcinoma progression and increases its sensitivity to lenvatinib through interaction with SPINK2.
Guo Y; Chai B; Zhang H; Chai X; Chen Y; Xu J; Qin L; Chai Y
Biol Direct; 2024 Feb; 19(1):15. PubMed ID: 38388961
[TBL] [Abstract][Full Text] [Related]
35. Integrin subunit beta 8 contributes to lenvatinib resistance in HCC.
Hou W; Bridgeman B; Malnassy G; Ding X; Cotler SJ; Dhanarajan A; Qiu W
Hepatol Commun; 2022 Jul; 6(7):1786-1802. PubMed ID: 35238496
[TBL] [Abstract][Full Text] [Related]
36. KDM6A promotes hepatocellular carcinoma progression and dictates lenvatinib efficacy by upregulating FGFR4 expression.
Guo W; Li S; Qian Y; Li L; Wang F; Tong Y; Li Q; Zhu Z; Gao WQ; Liu Y
Clin Transl Med; 2023 Oct; 13(10):e1452. PubMed ID: 37846441
[TBL] [Abstract][Full Text] [Related]
37. A positive feedback loop between Periostin and TGFβ1 induces and maintains the stemness of hepatocellular carcinoma cells via AP-2α activation.
Chen G; Wang Y; Zhao X; Xie XZ; Zhao JG; Deng T; Chen ZY; Chen HB; Tong YF; Yang Z; Ding XW; Guo PY; Yu HT; Wu LJ; Zhang SN; Zhu QD; Li JJ; Shan YF; Yu FX; Yu ZP; Xia JL
J Exp Clin Cancer Res; 2021 Jun; 40(1):218. PubMed ID: 34193219
[TBL] [Abstract][Full Text] [Related]
38. Expression of USP22 and Survivin is an indicator of malignant behavior in hepatocellular carcinoma.
Tang B; Liang X; Tang F; Zhang J; Zeng S; Jin S; Zhou L; Kudo Y; Qi G
Int J Oncol; 2015 Dec; 47(6):2208-16. PubMed ID: 26497847
[TBL] [Abstract][Full Text] [Related]
39. TM4SF1 upregulates MYH9 to activate the NOTCH pathway to promote cancer stemness and lenvatinib resistance in HCC.
Yang SB; Zhou ZH; Lei J; Li XW; Chen Q; Li B; Zhang YW; Ge YZ; Zuo S
Biol Direct; 2023 Apr; 18(1):18. PubMed ID: 37069693
[TBL] [Abstract][Full Text] [Related]
40. LINC00680 enhances hepatocellular carcinoma stemness behavior and chemoresistance by sponging miR-568 to upregulate AKT3.
Shu G; Su H; Wang Z; Lai S; Wang Y; Liu X; Dai L; Bi Y; Chen W; Huang W; Zhou Z; He S; Dai H; Tang B
J Exp Clin Cancer Res; 2021 Jan; 40(1):45. PubMed ID: 33499874
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
